Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy-Reference-Cited by-同舟云学术

Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy

Published:2021-08-22 Issue: Volume: Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Cuzick Jack M.¹^ORCID,Stone Steven²,Lenz Lauren²,Flake Darl D.²,Rajamani Saradha²,Moller Henrik³,Berney Daniel Maurice⁴,Cohen Todd²,Scardino Peter T.⁵

Affiliation:

1. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine Queen Mary University of London London UK

2. Myriad Genetics, Inc. Salt Lake City Utah USA

3. Department of Cancer Epidemiology, Population and Global Health King's College London London UK

4. Department of Molecular Oncology, Barts Cancer Institute Queen Mary University of London London UK

5. Department of Urology Memorial Sloan‐Kettering Cancer Center New York New York USA

Funder

Cancer Research UK

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1535

Reference22 articles.

1. National Cancer Institute Surveillance EaERSP.Prostate with Watchful Waiting Database (2010–2016): U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute: Surveillance Epidemiology and End Results (SEER) Program;2020.

2. 10‐year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer;Hamdy FC;N Engl J Med,2016

3. Follow‐up of prostatectomy versus observation for early prostate cancer;Wilt TJ;N Engl J Med,2017

4. Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline;Bekelman JE;J Clin Oncol,2018

5. CarrollPR ParsonsJK AndrioleG et al.NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection (Version 2.2019) NCCN Clinical Practice Guidelines in Oncology;2019.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer;JCO Precision Oncology;2024-05

2. Comparisons of cancer-specific and overall mortality in patients with biopsy- and TURP-diagnosed prostate cancer: a population-based propensity score-matching study;Journal of Men's Health;2024

3. Incidence and associated factors for incidental prostate cancer among patients who underwent surgery for benign prostatic hyperplasia: first report from Somalia;Journal of Cancer Research and Clinical Oncology;2022-08-29